297 research outputs found

    An Approach to Detect the Origin and Distribution of Software Defects in an Evolving Cyber-Physical System

    Get PDF
    Cyber-Physical Systems (CPS) are usually developed by an incremental approach. A changing environment like demanding user requirements or legislation amendments lead often to multiple development paths in an evolving CPS. Hence, software variability plays an increasingly important role adapting the characteristics of such CPS to different contexts. This paper focuses on software variability realized through a Software Product Line (SPL) more specifically. Thereby, variability and evolution are usually managed in different tools. However with respect to software defects, a holistic handling of variability and evolution is necessary to ensure a reliable software defect removal. Particularly, detecting software defects in different evolution stages and derived variants is ordinary, but complex and error-prone. To close the gap between variability and evolution, this paper presents a systematic approach to combine both disciplines. In particular, we apply existing variant management techniques in combination with software configuration management methods to determine a software defect's origin and distribution in an evolving SPL. We apply our approach to a CPS from the automotive domain to show its industrial relevance and usefulness

    Synthese S/N-funktionalisierter Dipeptide als Hemmstoffe von Zinkendoproteasen

    Get PDF
    Eine Reihe potentieller neuer Hemmstoffe der Zinkendoproteasen Thermolysin (TLN) und der Matrixmetalloproteasen (MMPŽs) wurden entwickelt. Einem Substrat-basierten Ansatz folgend wurde ein Dipeptid als Grundgerüst eingesetzt, das mit funktionellen Gruppen verknüpft wurde, die Zink-bindende Eigenschaften erwarten ließen. Diese basierten vorzugsweise auf bisher nicht untersuchten S-/N-funktionellen Strukturen. Als Dipeptid-Grundgerüst dienten vorzugsweise Leu-Phe und Leu-Trp. Als potentielle Zink-bindende Gruppen wurden neben Hydroxamsäure, Carbonsäure und Thiol, Sulfonamide, Sulfinamide, Sulfinylharnstoffe, Sulfonylharnstoffe, Sulfonimidoylharnstoffe, Sulfodiimide, sowie die Sulfoximidocarbonylgruppe, Sulfodiimidocarbonylgruppe und die N-Sulfamoylgruppe verwendet. Die Umsetzung von verschiedenen Aminosäureestern und Dipeptiden mit Diphenyl-N-sulfamoyl-iminocarbonat führte zur Einführung der N-Sulfamoyliminophenoxymethylgruppe die weiter zur N-Sulfamoylcarbamimidoylgruppe umgesetzt wurde. Die Reaktion der Dipeptide mit N-Cyaniminokohlensäurediphenylester führte zu Cyaniminophenoxymethyl-N-substituierten Dipeptiden, die weiter zum 3-Amino-1,2,4-triazol, 3-Amino-1-methyl-1,2,4-triazol und 5-Amino-1-oxa-2,4-diazol cyclisiert werden konnten. Die Hydroxamsäure, Carbonsäure, das Thiol, die N-Tosyl-Dipetide, die Sulfinylharnstoffe und das 3-Amino-1,2,4-triazol hemmten die Matrixmetalloproteasen im mikromolaren Bereich. Ein Sulfonimidoylharnstoff zeigte eine schwache Hemmung im mikromolaren Bereich gegen Thermolysin. Die N-Sulfamoyl-Dipeptide wurden gegen die humanen Carboanhydrasen I und II getestet und zeigten hemmende Eigenschaften im mikromolaren Bereich

    TanDEM-X Acquisition Planning and DEM Performance in the Third Year of Operation

    Get PDF
    TanDEM-X is a spaceborne SAR mission with the goal to derive a global Digital Elevation Model (DEM). The two incorporated satellites fly in a close formation with distances of around 500 m. These small baselines form a single pass bistatic interferometer for accurate DEM acquisitions. The final DEM product will enter a new level of detail and accuracy on a global scale. The absolute height error shall be less than 10 m in a 90% confidence interval at a pixel spacing of 12 m. The vertical height specification for the TanDEM-X mission foresees a 90% point-to-point error of 2 m (4 m) for areas with predominant terrain slopes smaller than 20% (greater than 20%) for a 1° by 1° cell. This presentation gives an overview about the planning and the actual status of the global DEM acquisition. This includes the acquisition plan after the first two years of operation, i. e. two global coverages, including the acquisitions of the Antarctica and difficult terrain. Also, the actual performance status in terms of absolute and relative height error and the narrow relation between the DEM acquisition planning and the performance evaluation is presented

    Silicon Promotes Exodermal Casparian Band Formation in Si-Accumulating and Si-Excluding Species by Forming Phenol Complexes

    Get PDF
    We studied the effect of Silicon (Si) on Casparian band (CB) development, chemical composition of the exodermal CB and Si deposition across the root in the Si accumulators rice and maize and the Si non-accumulator onion. Plants were cultivated in nutrient solution with and without Si supply. The CB development was determined in stained root cross-sections. The outer part of the roots containing the exodermis was isolated after enzymatic treatment. The exodermal suberin was transesterified with MeOH/BF3 and the chemical composition was measured using gas chromatography-mass spectroscopy (GC-MS) and flame ionization detector (GC-FID). Laser ablation-inductively coupled plasma-mass spectroscopy (LA-ICP-MS) was used to determine the Si deposition across root cross sections. Si promoted CB formation in the roots of Si-accumulator and Si non-accumulator species. The exodermal suberin was decreased in rice and maize due to decreased amounts of aromatic suberin fractions. Si did not affect the concentration of lignin and lignin-like polymers in the outer part of rice, maize and onion roots. The highest Si depositions were found in the tissues containing CB. These data along with literature were used to suggest a mechanism how Si promotes the CB development by forming complexes with phenols.DFG/SCHR 506/12-

    NCBP3 positively impacts mRNA biogenesis

    Get PDF
    The nuclear Cap-Binding Complex (CBC), consisting of Nuclear Cap-Binding Protein 1 (NCBP1) and 2 (NCBP2), associates with the nascent 5' cap of RNA polymerase II transcripts and impacts RNA fate decisions. Recently, the C17orf85 protein, also called NCBP3, was suggested to form an alternative CBC by replacing NCBP2. However, applying protein-protein interaction screening of NCBP1, 2 and 3, we find that the interaction profile of NCBP3 is distinct. Whereas NCBP1 and 2 identify known CBC interactors, NCBP3 primarily interacts with components of the Exon Junction Complex (EJC) and the TRanscription and EXport (TREX) complex. NCBP3-EJC association in vitro and in vivo requires EJC core integrity and the in vivo RNA binding profiles of EJC and NCBP3 overlap. We further show that NCBP3 competes with the RNA degradation factor ZC3H18 for binding CBC-bound transcripts, and that NCBP3 positively impacts the nuclear export of polyadenylated RNAs and the expression of large multi-exonic transcripts. Collectively, our results place NCBP3 with the EJC and TREX complexes in supporting mRNA expression

    Rationale and design of the MULTISTARS AMI Trial: a randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease

    Get PDF
    Background: About half of patients with acute ST-segment elevation myocardial infarction (STEMI) present with multivessel coronary artery disease (MVD). Recent evidence supports complete revascularization in these patients. However, optimal timing of non-culprit lesion revascularization in STEMI patients is unknown because dedicated randomized trials on this topic are lacking. Study design: The MULTISTARS AMI trial is a prospective, international, multicenter, randomized, two-arm, open-label study planning to enroll at least 840 patients. It is designed to investigate whether immediate complete revascularization is non-inferior to staged (within 19-45 days) complete revascularization in patients in stable hemodynamic conditions presenting with STEMI and MVD and undergoing primary percutaneous coronary intervention (PCI). After successful primary PCI of the culprit artery, patients are randomized in a 1:1 ratio to immediate or staged complete revascularization. The primary endpoint is a composite of all-cause death, non-fatal myocardial infarction, ischemia-driven revascularization, hospitalization for heart failure, and stroke at 1 year. Conclusions: The MULTISTARS AMI trial tests the hypothesis that immediate complete revascularization is non-inferior to staged complete revascularization in stable patients with STEMI and MVD
    corecore